Stocks Health care BOLT
NASDAQ · Health careBolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. brought in $4.7M of revenue over the twelve months to June 30, 2026, up 12.8% from a year earlier. It posted a net loss of $28.7M. In fiscal 2025 capital spending exceeded operating cash flow by $39.9M. At June 30, 2026 it held $12.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
Watch BOLT in 60 secondsWhat Bolt Biotherapeutics, Inc. does
Bolt Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BOLT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.7M | -$33.4M | -$17.85 | -$39.9M |
| 2024 | $7.7M | -$63.1M | -$33.06 | -$61.3M |
| 2023 | $7.9M | -$69.2M | -$36.67 | -$69.7M |
| 2022 | $5.7M | -$88.1M | -$47.29 | -$78.5M |
| 2021 | $1.3M | -$98.6M | -$59.51 | -$59.4M |
| 2021 | $231K | -$60.7M | -$578.85 | -$50.6M |
Full financial statements: income, balance sheet and cash flow
Where BOLT ranks in Health care
Latest SEC filings
What Bolt Biotherapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 100% to $5K versus the same quarter last year; diluted EPS -$4.57 versus -$4.46.
- August 11, 2026
- June 11, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 98% to $26K versus the same quarter last year; diluted EPS -$4.31 versus -$5.76.
- May 12, 2026
- April 28, 2026
- April 28, 2026Additional proxy material DEFA14A
- April 28, 2026Proxy statement DEF 14A
- March 12, 2026
Insider trades
What the people running Bolt Biotherapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $128.3K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Quinn William P.President, CEO and CFO, Director | Sold | 9,132 | $29.6K |
| September 18, 2026 | Nemec SarahSenior VP, Finance and PAO | Sold | 4,077 | $13.2K |
| September 18, 2026 | Yonehiro GrantChief Operating Officer | Sold | 6,850 | $22.2K |
| September 17, 2026 | Quinn William P.President, CEO and CFO, Director | Sold | 6,545 | $21.7K |
| September 17, 2026 | Nemec SarahSenior VP, Finance and PAO | Sold | 2,922 | $9.7K |
| September 17, 2026 | Yonehiro GrantChief Operating Officer | Sold | 4,909 | $16.3K |
| September 16, 2026 | Quinn William P.President, CEO and CFO, Director | Sold | 1,889 | $7.1K |
| September 16, 2026 | Nemec SarahSenior VP, Finance and PAO | Sold | 843 | $3.2K |
| September 16, 2026 | Yonehiro GrantChief Operating Officer | Sold | 1,417 | $5.3K |
| June 5, 2026 | Quinn William P.President, CEO and CFO, Director | Bought | 637 | $2.5K |
| June 5, 2026 | Nemec SarahSenior VP, Finance and PAO | Bought | 509 | $2K |
Who owns BOLT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Renaissance Technologies LLC13G, passive with 1 related filers | 5.13% | August 13, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 59,735 shares in total, about $213.9K at the last price.
| Holder | Shares |
|---|---|
| Quinn William P.President, CEO and CFO, Director | 25,384 |
| Yonehiro GrantChief Operating Officer | 17,269 |
| Nemec SarahSenior VP, Finance and PAO | 17,082 |
Questions about BOLT
What does Bolt Biotherapeutics, Inc. do?
Bolt Biotherapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BOLT.
Is Bolt Biotherapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $28.7M on revenue of $4.7M.
How much revenue does Bolt Biotherapeutics, Inc. make?
Over the twelve months to June 30, 2026 Bolt Biotherapeutics, Inc. reported revenue of $4.7M. That is 12.8% more than a year earlier.
When did Bolt Biotherapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.
Similar companies
Compare BOLT with
Follow BOLT
Get an email when Bolt Biotherapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BOLT: get an email when it filesWhere the numbers come from
Financial figures are the values Bolt Biotherapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.